Skip to main content
Premium Trial:

Request an Annual Quote

Inostics' Lab Gains CLIA Licensure

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.

The blood-based test is based on Beaming — or Beads, Emulsions, Amplification, and Magnetics — technology that combines emulsion-based digital PCR with flow cytometry. Inostics said the technology allows for the molecular analysis of tumor DNA shed from primary and metastatic tumors found circulating in a patient's blood.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making," Frank Diehl, CSO of Inostics, said in a statement.

Inostics is based in Hamburg, Germany and specializes in mutation detection. Aside from the Beaming technology, its other main technology is Plasma-Sequencing which uses next-generation sequencing technology for detecting mutations in plasma DNA.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.